Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

NCT05282069
completedphase_1

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

NCT05991401
completedphase_1

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

NCT05992428
completedphase_2

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

NCT03566134

Clinical Trials (4)

Showing 4 of 4 trials
NCT05282069Phase 3

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Completed
NCT05991401Phase 1

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Completed
NCT05992428Phase 1

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
NCT03566134Phase 2

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4